Abstract
OPC-14597 {aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects. These studies characterized the molecular pharmacology of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone derivative OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors. All three compounds exhibited highest affinity for D(2L) and D(2S) receptors relative to the other cloned receptors examined. Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D(2L) receptors, although the metabolite DM-1451 behaved as a pure antagonist. These data suggest that clinical atypicality can occur with drugs that exhibit selectivity for D(2L)/D(2S) rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compound interacting with a single dopamine receptor subtype (D2) in distinct cellular locales. Copyright (C) 1999 American College of Neuropsychopharmacology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 612-627 |
| Number of pages | 16 |
| Journal | Neuropsychopharmacology |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 1999 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Psychiatry and Mental health
Cite this
}
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. / Lawler, Cindy P.; Prioleau, Cassandra; Lewis, Mechelle; Mak, Chun; Jiang, Dong; Schetz, John A.; Gonzalez, Antonio M.; Sibley, David R.; Mailman, Richard.
In: Neuropsychopharmacology, Vol. 20, No. 6, 01.06.1999, p. 612-627.Research output: Contribution to journal › Article
TY - JOUR
T1 - Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
AU - Lawler, Cindy P.
AU - Prioleau, Cassandra
AU - Lewis, Mechelle
AU - Mak, Chun
AU - Jiang, Dong
AU - Schetz, John A.
AU - Gonzalez, Antonio M.
AU - Sibley, David R.
AU - Mailman, Richard
PY - 1999/6/1
Y1 - 1999/6/1
N2 - OPC-14597 {aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects. These studies characterized the molecular pharmacology of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone derivative OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors. All three compounds exhibited highest affinity for D(2L) and D(2S) receptors relative to the other cloned receptors examined. Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D(2L) receptors, although the metabolite DM-1451 behaved as a pure antagonist. These data suggest that clinical atypicality can occur with drugs that exhibit selectivity for D(2L)/D(2S) rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compound interacting with a single dopamine receptor subtype (D2) in distinct cellular locales. Copyright (C) 1999 American College of Neuropsychopharmacology.
AB - OPC-14597 {aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects. These studies characterized the molecular pharmacology of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone derivative OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors. All three compounds exhibited highest affinity for D(2L) and D(2S) receptors relative to the other cloned receptors examined. Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D(2L) receptors, although the metabolite DM-1451 behaved as a pure antagonist. These data suggest that clinical atypicality can occur with drugs that exhibit selectivity for D(2L)/D(2S) rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compound interacting with a single dopamine receptor subtype (D2) in distinct cellular locales. Copyright (C) 1999 American College of Neuropsychopharmacology.
UR - http://www.scopus.com/inward/record.url?scp=0033151286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033151286&partnerID=8YFLogxK
U2 - 10.1016/S0893-133X(98)00099-2
DO - 10.1016/S0893-133X(98)00099-2
M3 - Article
C2 - 10327430
AN - SCOPUS:0033151286
VL - 20
SP - 612
EP - 627
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 6
ER -